课题基金 / 基金详情

Complement activation and angiogenic imbalance in pregnancy and hypertension

Complement activation and angiogenic imbalance in pregnancy and hypertension
妊娠和高血压中的补体激活和血管生成失衡
批准号:
8179940
负责人:
JEAN F. REGAL
金额:
$44.57万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2013-07-31

项目摘要

项目成果

JEAN F. REGAL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在了解怀孕期间胎盘缺血如何导致母亲高血压和儿童宫内生长受限(IUGR)方面存在根本差距。在妊娠期高血压的研究中,研究重点是促血管生成因子(血管内皮生长因子)和抗血管生成因子(可溶性FMS样酪氨酸激酶-1、可溶性endoglin)导致高血压的平衡。在补体系统与妊娠的研究中,研究重点集中在血管生成失衡导致的免疫调节事件中的胎儿丢失。建议的研究测试补体系统和胎盘缺血后高血压之间的关键机制联系。长期目标:确定操纵补体系统以预防先兆子痫或将母婴后果降至最低的治疗效用。当前建议的总体目标是在大鼠子宫胎盘灌流压降低(RUPP)模型中确定补体激活是导致不良母婴后果的关键事件,该模型与先兆子痫相关的高血压非常相似。这种妊娠晚期大鼠胎盘缺血模型的特点是血管生成失衡、内皮功能障碍、高血压和IUGR;所有这些都是人类先兆子痫的特征。关于胎盘缺血后事件的中心假说是,补体激活导致补体裂解产物C5a的产生和胎盘中性粒细胞的浸润,导致血管生成失衡、内皮功能障碍、高血压和IUGR。具体目标#1:确定补体激活和C5a的生成是胎盘中性粒细胞浸润、血管生成失衡以及由此导致的内皮功能障碍、高血压和胎盘缺血引起的宫内发育迟缓的关键事件。体内研究将评估补体激活,并确定抑制补体激活和拮抗C5a受体的效果。对胎盘外植体、滋养层细胞和炎症细胞进行的体外研究将确定补体激活是否直接改变了胎盘血管生成的平衡,或者需要炎症细胞的渗透。具体目标2:确定胎盘中性粒细胞浸润是导致血管生成失衡以及由此导致的内皮功能障碍、高血压和胎盘缺血引起的宫内发育迟缓的关键事件。体内研究将评估中性粒细胞耗尽的影响。这项拟议的研究具有创新性,因为它将补体系统和炎症方面的基本专业知识与妊娠高血压综合征的动物模型结合起来,以研究血管生成失衡之前的新机制途径,并导致母婴的不良后果。这些研究将确定补体系统激活和中性粒细胞堆积作为复杂妊娠高血压和宫内发育迟缓的原因的重要性。这一贡献将是重要的,因为它将确定操纵补体系统或中性粒细胞聚集是否是预防和/或治疗与子痫前期相关的高血压的可行治疗方案。 公共卫生相关性:拟议的研究与公共健康相关,因为先兆子痫和相关的妊娠高血压疾病影响到美国约10%的怀孕,对母亲和孩子的健康都有重大影响。先兆子痫是导致产妇死亡(18%)和早产(15%)的主要原因。该项目与NIH的使命相关,因为将补体系统激活与高血压和宫内生长受限联系起来的机制研究将确定操纵补体系统或中性粒细胞渗透来治疗和/或预防先兆子痫高血压的潜在治疗益处,并可能将对母婴的不良后果降至最低。
英文摘要
DESCRIPTION (provided by applicant): There is a fundamental gap in understanding how placental ischemia during pregnancy leads to hypertension in the mother and intrauterine growth restriction (IUGR) of the child. In studies of hypertension in pregnancy, the research focus is on the balance of pro-angiogenic factors (vascular endothelial growth factor) and anti-angiogenic factors (soluble fms-like tyrosine kinase-1, soluble endoglin) leading to hypertension. In studies of complement system and pregnancy the research focus is on angiogenic imbalance leading to fetal loss in immune mediated events. The proposed studies test the critical mechanistic link between complement system and hypertension following placental ischemia. Long term goal: Determine the therapeutic utility of manipulating the complement system to prevent preeclampsia or minimize maternal/fetal consequences. Overall objective of the current proposal is to identify complement activation as a critical event leading to adverse maternal/fetal consequences in the reduced uteroplacental perfusion pressure (RUPP) model in the rat that closely mimics hypertension associated with preeclampsia. This model of placental ischemia in the 3rd trimester pregnant rat is characterized by angiogenic imbalance, endothelial dysfunction, hypertension and IUGR; all characteristics of preeclampsia in humans. The central hypothesis for events following placental ischemia is that complement activation leads to generation of the complement cleavage product C5a and placental neutrophil infiltration resulting in angiogenic imbalance, endothelial dysfunction, hypertension and IUGR. Specific Aim #1: Identify complement activation and generation of C5a as a critical event for placental neutrophil infiltration, angiogenic imbalance and the resultant endothelial dysfunction, hypertension, and IUGR caused by placental ischemia. In vivo studies will assess complement activation and determine the effect of inhibiting complement activation and antagonizing the C5a receptor. In vitro studies with placental explants, trophoblast cells and inflammatory cells will determine if complement activation directly alters angiogenic balance in the placenta or requires infiltration of inflammatory cells. Specific Aim 2: Identify placental neutrophil infiltration as a critical event leading to angiogenic imbalance and the resultant endothelial dysfunction, hypertension, and IUGR caused by placental ischemia. In vivo studies will assess the effect of neutrophil depletion. The proposed research is innovative because it couples essential expertise in the complement system and inflammation with animal models of pregnancy induced hypertension to investigate novel mechanistic pathways that precede angiogenic imbalance and lead to adverse consequences for mother and child. These studies will determine the importance of complement system activation and neutrophil accumulation as a cause of hypertension and IUGR in complicated pregnancies. This contribution will be significant because it will determine if manipulation of the complement system or neutrophil accumulation is a feasible therapeutic option for prevention and/or treatment of hypertension associated with preeclampsia. PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health because preeclampsia and related hypertensive disorders of pregnancy affect ~10% of all pregnancies in the United States, significantly impacting the health of both mother and child. Preeclampsia is a leading cause of maternal death (18%) and premature birth (15%). The project is relevant to the mission of NIH because mechanistic studies linking complement system activation to hypertension and intrauterine growth restriction will determine the potential therapeutic benefit of manipulating the complement system or neutrophil infiltration to treat and/or prevent the hypertension of preeclampsia and potentially minimize adverse consequences for both mother and child.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Complement Activation in Pregnancy and Hypertension
  • 批准号:
    8574333
  • 项目类别:
  • 资助金额:
    $43.72万
  • 财政年份:
    2011
  • 负责人:
    JEAN F. REGAL
  • 依托单位:
IMMUNOTOXICITY OF ACID ANHYDRIDES IN THE LUNG
  • 批准号:
    2459007
  • 项目类别:
  • 资助金额:
    $18.05万
  • 财政年份:
    1996
  • 负责人:
    JEAN F. REGAL
  • 依托单位:
IMMUNOTOXICITY OF ACID ANHYDRIDES IN THE LUNG
  • 批准号:
    2156803
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    1996
  • 负责人:
    JEAN F. REGAL
  • 依托单位:
IMMUNOTOXICITY OF ACID ANHYDRIDES IN THE LUNG
  • 批准号:
    2749675
  • 项目类别:
  • 资助金额:
    $18.77万
  • 财政年份:
    1996
  • 负责人:
    JEAN F. REGAL
  • 依托单位:
海外基金